FDA won't approve Summit, Akeso's ivonescimab
The FDA has said it cannot approve Summit /Akeso's ivonescimab, delaying a drug that could usher in a new era of dual-acting cancer immunotherapies.
Windward Bio catches $175m from its IPO
Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.
Neurosterix' $105m round leads the week's biotech financings
Neurosterix raises $105m for its schizophrenia candidate, as Delix, VectorY, and Eli Radiopharma also add to their cash reserves.
Rapid DEA review clears way for Takeda's narcolepsy launch
Takeda has started to roll out its new narcolepsy therapy in the US, with competitive pricing to Jazz Pharma's current market leader Xywav.
Microsoft outage disrupting healthcare; reports
There are reports of disruption to health services around the world as a result of the Microsoft outage, with the UK's NHS said to be badly affected.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
The PM Awards aren’t just for agencies. They’re for the peop...
For decades, the PM Awards have been a fixture in the pharma and healthcare communications calendar
PMi Awards 2026: innovation, connection and a changing indus...
One of the things I enjoyed most about this year’s PM Society PMi Awards was the sheer breadth of the community in the room.
LEAP HR: Life Sciences Europe
Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences
Rational Based Drug Design Summit Europe
Driving Safer, Faster & More Efficient Discovery Across Europe
Evolution Summit 2027 to Convene Senior Clinical Development...
Westlake Village, CA: Marcus Evans today announced the Evolution Summit 2027, an invitation-only gathering of senior clinical trial executives